2 Small-Cap Stocks Rising on New "Buy" Ratings

B. Riley predicted strong sales of imetelstat after FDA approval

Jan 31, 2019 at 11:44 AM
facebook X logo linkedin


B. Riley upgraded Geron Corporation (NASDAQ:GERN) to "buy" from "neutral," and raised its price target to $3.25 from $1.50 -- a 215% premium to last night's close. The analyst in coverage waxed optimistic on the drugmaker's myelofibrosis treatment imetelstat, projecting approval from the Food and Drug Administration (FDA) by 2023, and U.S. sales of $750 million by 2026.

In response, GERN stock is up 7.8% to trade at $1.11, but remains well off its mid-September high of $6.99. On Sept. 27, the shares gapped down nearly 63% after Johnson & Johnson (JNJ) terminated its imetelstat collaboration with Geron, and have been trending lower ever since.  And while the equity has come off its Dec. 21 record low of $0.95, the rebound is running out of steam near the 40-day moving average.

gern stock daily chart jan 31

H.C. Wainwright initiated coverage on Mesoblast Limited (NASDAQ:MESO) with a "buy" rating and $6.50 price target, representing expected upside of 43% to Wednesday's close at $4.54. The brokerage firm called MESO's product pipeline "mature," and said its proprietary platform has been validated by the approval of TEMCELL and Alofisel in the U.K. and Japan.

After being down as much as 3% earlier, MESO stock has bounced from its 40-day moving average to trade up 0.2% at $4.55. The shares bottomed at a nine-year low of $3.35 on Dec. 24, and eventually rallied back up near $5 -- a level that's served as both support and resistance over the last 12 months.

meso stock daily chart jan 31

Most analysts are already bullish on Mesoblast, with 80% of those in coverage maintaining a "buy" rating ahead of today, and not a single "sell" on the books. Plus, the average 12-month price target sits all the way up at $14.55.

 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI